21:37 , Feb 14, 2019 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: January 2019

New Therapeutic Targets and Biomarkers: January 2019 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during January. Therapeutic targets are defined as any protein, gene or other molecule...
01:07 , Jan 8, 2019 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Anxiety Mouse studies suggest depleting senescent cells could help treat obesity-induced anxiety. In a transgenic mouse model of obesity expressing the senescence marker human CDKN2A, a tool compound that depletes CDKN2A-positive cells decreased anxiety-like...
13:47 , Jan 3, 2019 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Liver cancer Patient sample and mouse studies suggest inhibiting CDK20 could help treat non-alcoholic steatohepatitis (NASH)-associated hepatocellular carcinoma (HCC). In tumor samples from patients, levels of CDK20 were higher than in matched normal liver...
19:29 , Dec 21, 2018 |  BC Week In Review  |  Clinical News

G1's trilaciclib leads to PFS of up to 8.8 months in Phase II for TNBC

G1 Therapeutics Inc. (NASDAQ:GTHX) said trilaciclib (G1T28) administered on the day of chemotherapy led to a preliminary median progression-free survival (PFS) of 8.8 months vs. 5.4 months for chemotherapy alone in a Phase II trial...
20:48 , Dec 19, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer Patient sample, cell culture and mouse studies suggest inhibiting the BRD4-FOXO3-CDK6 axis could help treat luminal breast cancer resistant to AKT inhibitors. In patients who had been treated for hormone receptor-positive luminal...
13:09 , Dec 4, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Ovarian cancer Cell culture and mouse studies identified a CDK7/CDK12/CDK13 inhibitor that could help treat ovarian cancer. Screening of 42 small molecules targeting transcriptional and/or epigenetic components in two human ovarian cancer cell lines...
19:06 , Nov 30, 2018 |  BC Week In Review  |  Clinical News

MMRF launches MyDRUG multiple myeloma platform trial

The Multiple Myeloma Research Foundation launched the collaborative MyDRUG platform trial to identify new treatment options for molecularly defined subgroups of patients. The Phase I/II signal-finding study builds upon the patient group's 2011 CoMMpass trial,...
18:34 , Nov 30, 2018 |  BC Week In Review  |  Clinical News

G1 falls as trilaciclib shows myeloprotective effects but no response benefit in first-line SCLC

G1 Therapeutics Inc. (NASDAQ:GTHX) shares fell $4.54 (11%) to $35.39 Nov. 27 after Phase II data showed that the company’s trilaciclib plus Tecentriq atezolizumab and chemotherapy failed to show an improvement in overall response rate...
04:50 , Nov 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Revving up metabolism at ASH 2018

Cancer metabolism is a prominent theme at this year’s ASH meeting, with researchers broadening the tent from metabolic targets that drive hematologic malignancies to those that intersect with other hot topics, notably immuno-oncology and epigenetics....
15:49 , Nov 29, 2018 |  BC Extra  |  Clinical News

MMRF launches MyDRUG multiple myeloma platform trial

The Multiple Myeloma Research Foundation launched the collaborative MyDRUG platform trial to identify new treatment options for molecularly defined subgroups of patients. The Phase I/II signal-finding study builds upon the patient group's 2011 CoMMpass trial,...